Atrium Therapeutics, Inc (RNA) insider trading
Every open-market stock purchase and sale by Atrium Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $5.6M over the last 12 months (16 sales). No open-market buys.
- Last insider buy: Roderick Wong (C-suite exec), $14.4M, 5 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $5.6M (16 sales). Last close $11.55 on Jun 7, 2026.
Recent RNA insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Apr 20, 2026 | Husam Younis (C-suite exec) | Bought (not open market) | — |
| Apr 20, 2026 | Stephanie Kenney (Insider) | Bought (not open market) | — |
| Apr 20, 2026 | Steven George Hughes (C-suite exec) | Bought (not open market) | — |
| Apr 20, 2026 | Steven George Hughes (C-suite exec) | Bought (not open market) | — |
| Apr 20, 2026 | Brendan R. Winslow (CFO) | Bought (not open market) | — |
| Apr 20, 2026 | Brendan R. Winslow (CFO) | Bought (not open market) | — |
| Apr 20, 2026 | Kathleen P. Gallagher (Insider) | Bought (not open market) | — |
| Apr 20, 2026 | Kathleen P. Gallagher (Insider) | Bought (not open market) | — |
| Apr 20, 2026 | Rocio Martin Hoyos (C-suite exec) | Bought (not open market) | — |
| Apr 20, 2026 | Stephanie Kenney (Insider) | Bought (not open market) | — |
| Apr 20, 2026 | Rocio Martin Hoyos (C-suite exec) | Bought (not open market) | — |
| Apr 20, 2026 | Husam Younis (C-suite exec) | Bought (not open market) | — |
| Feb 27, 2026 | Sarah Boyce (Insider) | Bought (not open market) | — |
| Feb 27, 2026 | Simona Skerjanec (Insider) | Bought (not open market) | — |
| Feb 27, 2026 | W. Michael Flanagan (Insider) | Bought (not open market) | — |
| Feb 27, 2026 | Troy Edward Wilson (Insider) | Bought (not open market) | — |
| Feb 27, 2026 | Carsten Boess (Insider) | Bought (not open market) | — |
| Jan 21, 2026 | Sarah Boyce (CEO) | Sold | $579K |
| Jan 21, 2026 | Sarah Boyce (CEO) | Sold | $463K |
| Jan 21, 2026 | W. Michael Flanagan (C-suite exec) | Sold | $288K |
| Jan 21, 2026 | Steven George Hughes (C-suite exec) | Sold | $209K |
| Jan 21, 2026 | Michael F MacLean (CFO) | Sold | $198K |
| Jan 21, 2026 | W. Michael Flanagan (C-suite exec) | Sold | $185K |
| Jan 21, 2026 | Steven George Hughes (C-suite exec) | Sold | $146K |
| Jan 21, 2026 | Michael F MacLean (CFO) | Sold | $131K |
Who's trading RNA
- Rocio Martin Hoyos, C-suite exec: other filings, last Apr 20, 2026
- Steven George Hughes, C-suite exec: sold $631K (4 sales), last Apr 20, 2026
- Stephanie Kenney, Insider: other filings, last Apr 20, 2026
- Husam Younis, C-suite exec: other filings, last Apr 20, 2026
- Kathleen P. Gallagher, C-suite exec: other filings, last Apr 20, 2026
- Brendan R. Winslow, CFO: other filings, last Apr 20, 2026
- Carsten Boess, Director: other filings, last Feb 27, 2026
- Sarah Boyce, CEO: sold $1.7M (3 sales), last Feb 27, 2026
- W. Michael Flanagan, Officer: sold $645K (3 sales), last Feb 27, 2026
- Simona Skerjanec, Director: other filings, last Feb 27, 2026
- Troy Edward Wilson, Director: other filings, last Feb 27, 2026
- Teresa McCarthy, Officer: sold $1.4M (4 sales), last Jan 21, 2026
- Arthur A Levin, Director: sold $127K (1 sale), last Jan 21, 2026
- Michael F MacLean, CFO: sold $472K (3 sales), last Jan 21, 2026
- Charles Calderaro III, CTO: sold $269K (1 sale), last Jan 7, 2026
Get free alerts when an insider at Atrium Therapeutics, Inc files a new trade →